Screener
Aclaris Therapeutics ACRS Single Reportable — Research And Development Expense Personnel Charges
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept acrs:ResearchAndDevelopmentExpensePersonnelCharges.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| (In thousands) | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| ATI-9494 | 3,056 | 871 | 5,281 | 1,549 |
| Discovery | 1,972 | 749 | 3,411 | 1,417 |
| Total research and development project expense(1) | 13,632 | 7,003 | 24,109 | 14,160 |
| Personnel | 3,036 | 2,984 | 6,317 | 5,911 |
| Other research and development(2) | 1,398 | 1,462 | 3,297 | 2,962 |
| Total research and development | 18,066 | 11,449 | 33,723 | 23,033 |
| General and administrative(3) | 6,048 | 5,386 | 12,791 | 11,525 |
| Licensing | 1,235 | 1,335 | 2,628 | 2,345 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's single reportable — research and development expense personnel charges?
- Aclaris Therapeutics (ACRS) reported single reportable — research and development expense personnel charges of $3.04M in Q2 2026.
- How has Aclaris Therapeutics's single reportable — research and development expense personnel charges changed year-over-year?
- Aclaris Therapeutics's single reportable — research and development expense personnel charges increased by 1.7% year-over-year, from $2.98M to $3.04M.
- What does single reportable — research and development expense personnel charges mean?
- Includes all compensation, benefits, and related costs for staff dedicated to research and development activities within the segment. It measures the human capital investment required to sustain the company's scientific and clinical development efforts. High personnel charges indicate a significant investment in internal expertise and specialized talent.
Ask your AI about Aclaris Therapeutics's single reportable — research and development expense personnel charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude